Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ImExHS Limited (IME.AX)
Mascot, NSW, AU
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -7.89% | -11.39% | -22.22% | +16.67% | -12.50% | +6.06% | -38.05% | -80.77% | -95.31% | -95.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+9.0% Q4'25: +41.0% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+3.6% Q4'25: +105.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-1.4% Q4'25: +12.5% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-2.4% Q4'25: +1.0% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-5.3% Q4'25: +2.8% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+14.0% Q4'25: +28.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.37× ★ Q4'25: 0.11× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.91M
est: 10.02M (+9.0%)
|
13.37M
est: 13.40M (-0.2%)
|
17.12M
est: 17.10M (+0.1%)
|
19.67M
est: 24.90M (-21.0%)
|
26.57M
est: 27.00M (-1.6%)
|
28.97M
est: 29.00M (-0.1%)
|
32.59M
32.59M – 32.59M
+12.4% YoY
|
36.28M
36.28M – 36.28M
+11.3% YoY
|
39.80M
39.80M – 39.80M
+9.7% YoY
|
| EBITDA |
-1.30M
est: -901.0K (-44.7%)
|
-3.00M
est: -1.21M (-149.2%)
|
-744.2K
est: -1.54M (+51.6%)
|
-1.26M
est: 7.05M (-117.9%)
|
45.6K
est: 7.64M (-99.4%)
|
1.52M
est: 8.20M (-81.5%)
|
9.22M
9.22M – 9.22M
+12.4% YoY
|
10.26M
10.26M – 10.26M
+11.3% YoY
|
11.26M
11.26M – 11.26M
+9.7% YoY
|
| EBIT |
-2.33M
est: -1.89M (-23.2%)
|
-4.25M
est: -2.53M (-67.9%)
|
-2.50M
est: -3.23M (+22.4%)
|
-3.69M
est: 5.66M (-165.2%)
|
-2.11M
est: 6.14M (-134.3%)
|
-697.6K
est: 6.59M (-110.6%)
|
7.41M
7.41M – 7.41M
+12.4% YoY
|
8.25M
8.25M – 8.25M
+11.3% YoY
|
9.05M
9.05M – 9.05M
+9.7% YoY
|
| Net Income |
-3.62M
est: -399.6K (-805.0%)
|
-4.70M
est: -5.68M (+17.2%)
|
-3.04M
est: -2.97M (-2.4%)
|
-4.19M
|
-2.63M
est: -768.5K (-241.6%)
|
-2.88M
est: -3.53M (+18.5%)
|
1.07M
1.07M – 1.07M
+130.3% YoY
|
3.27M
3.27M – 3.27M
+205.6% YoY
|
4.97M
4.97M – 4.97M
+52.1% YoY
|
| SGA |
4.89M
est: 3.77M (+29.7%)
|
6.23M
est: 5.05M (+23.5%)
|
5.82M
est: 6.44M (-9.6%)
|
6.11M
est: 8.59M (-28.8%)
|
8.44M
est: 9.31M (-9.4%)
|
8.41M
est: 10.00M (-16.0%)
|
11.24M
11.24M – 11.24M
+12.4% YoY
|
12.51M
12.51M – 12.51M
+11.3% YoY
|
13.73M
13.73M – 13.73M
+9.7% YoY
|
| EPS |
-0.15
est: -0.01 (-1,587.7%)
|
-0.15
est: -0.13 (-18.8%)
|
-0.09
est: -0.07 (-29.4%)
|
-0.10
|
-0.06
est: -0.02 (-289.3%)
|
-0.06
est: -0.07 (+18.4%)
|
0.02
0.02 – 0.02
+130.3% YoY
|
0.06
0.06 – 0.06
+205.6% YoY
|
0.10
0.10 – 0.10
+52.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| German Arango | Co-Founder, Chief Executive Officer, MD & Executive Director | 426.9K | — |
| Reena Minhas | Chief Financial Officer & Company Secretary | 321.4K | female |
| Jorge Marin | Co-Founder & Chief Medical Officer | 189.8K | — |
| Andres Vanegas | Co-Founder & Strategic Accounts Manager | 139.7K | male |
| Benjamin Brinquis | Head of Growth | — | male |
| Alexander Sanz | Co-Founder | — | male |
| Juan David Fajardo | VP of Global Sales | — | male |
| Orlando Joven | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IME.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
